Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cinqair
Marketing
Which asthma biologic is the most popular of them all?
In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.
Angus Liu
Nov 21, 2019 11:35am
Novartis' Xolair eyes sinusitis to backstop blockbuster sales
Jun 4, 2019 12:51pm
Sanofi's Dupixent set for $2.5B in peak asthma sales: analyst
Oct 22, 2018 12:40pm
5 antibody drugs for asthma show benefits but cost too much—ICER
Sep 26, 2018 12:11pm
AZ, shut out of COPD, touts long-term Fasenra asthma data
Sep 18, 2018 11:01am
Flopped trials dash Teva's hopes for subcutaneous Cinqair
Jan 22, 2018 10:32am
